Farmorubicin 2 mg/ml (IV Infusion)

Indications

• Adjuvant therapy for breast cancer with axillary node tumor involvement

Pharmacology

• Cytotoxic properties
• Inhibits DNA and RNA synthesis
• Distribution into tissues
• Metabolism by the liver and other organs
• Excretion through biliary and urinary routes

Dosage & Administration

• Intravenous infusion
• Repeated 3 to 4-week cycles
• Recommended dose of 100 to 120 mg/m²
• Specific regimens like CEF-120 and FEC-100

Interactions

• Interaction with cardioactive compounds and cytotoxic drugs
• Effects of Paclitaxel, Docetaxel, and radiation therapy
• Hepatic function affect Farmorubicin metabolism

Contraindications

• Hypersensitivity to Epirubicin or anthracyclines

Side Effects

• Myelosuppression
• Cardiotoxicity
• Alopecia
• Nausea
• Vomiting
• Rash
• Harmless reddish appearance of urine

Pregnancy & Lactation

• Pregnancy Category D
• Unknown excretion in human milk

Precautions & Warnings

• Storage conditions at refrigerated conditions
• Baseline assessment before treatment
• Monitoring for myelosuppression and cardiotoxicity
• Supportive care for severe complications

Use in Special Populations

• Dosage adjustments based on toxicities
• Considerations for bone marrow dysfunction, hepatic impairment, renal impairment
• Uncertain safety and effectiveness in pediatric patients
• Monitoring toxicity in elderly female patients

Overdose Effects

• Supportive treatment in case of overdose
• Observation for delayed CHF

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Store in refrigerator or at 2-8°C
• Protection from light and children

Related Brands